Published in Cancer Res on October 01, 2000
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res (2008) 2.19
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer (2003) 2.03
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer (2007) 1.46
Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets (2011) 1.36
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol (2014) 1.32
Apoptosis: targets in pancreatic cancer. Mol Cancer (2003) 1.31
Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer (2008) 1.26
AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer (2003) 1.22
Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal (2013) 1.17
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer (2012) 1.15
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res (2008) 1.14
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J (2006) 1.11
Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. J Gastroenterol (2008) 1.03
The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res (2010) 1.02
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res (2005) 1.00
Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep (2010) 0.99
Basic principles and technologies for deciphering the genetic map of cancer. World J Surg (2009) 0.96
Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol (2011) 0.96
Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol (2002) 0.95
Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. Int J Clin Exp Pathol (2012) 0.94
Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol (2014) 0.94
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer (2011) 0.91
Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol (2010) 0.90
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med (2011) 0.88
Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials (2015) 0.88
ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncol Rep (2011) 0.88
Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma. Int J Mol Sci (2012) 0.88
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis. Mol Cancer Ther (2012) 0.86
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer (2005) 0.86
Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. FEBS Lett (2005) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer. Gut (2005) 0.84
Pancreatic cancer: translational research aspects and clinical implications. World J Gastroenterol (2012) 0.83
Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res (2012) 0.83
Potential roles for prions and protein-only inheritance in cancer. Cancer Metastasis Rev (2012) 0.82
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs (2010) 0.80
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway. Cell Death Dis (2015) 0.80
Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. BMC Cancer (2016) 0.78
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol (2009) 0.77
Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale (2015) 0.77
Role of autophagy in apoptotic regulation by Akt in pancreatic cancer. Anticancer Res (2014) 0.77
The PI3K Pathway: Background and Treatment Approaches. Breast Care (Basel) (2016) 0.76
RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells. Genes Cancer (2014) 0.76
Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br J Clin Pharmacol (2015) 0.75
Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. Oncol Rep (2016) 0.75
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC Cancer (2014) 0.75
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Invest New Drugs (2015) 0.75
High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma. Surgeon (2009) 0.75
Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol (2016) 0.75
A phase I study of topotecan and gemcitabine in advanced solid tumors. Invest New Drugs (2010) 0.75
Cytotoxic effects exerted by pentachlorophenol by targeting nodal pro-survival signaling pathways in human pancreatic cancer cells. Toxicol Rep (2014) 0.75
High apoptosis-inducing and antitumor activities of the products of biological but not chemical cyclophosphamide activation. Dokl Biol Sci (2002) 0.75
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem (1983) 9.40
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 8.37
Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol (1996) 4.25
Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol (2000) 4.19
Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet (2001) 3.45
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res (2000) 3.24
Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol (1984) 2.39
Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg (1997) 2.09
A diploid epithelial cell line from normal adult rat liver with phenotypic properties of 'oval' cells. Exp Cell Res (1984) 1.91
Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol (1992) 1.85
Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol (1998) 1.82
Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry (1985) 1.78
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
Disruption of the terminal base pairs of retroviral DNA during integration. Genes Dev (1997) 1.69
Effect of knowledge of chronologic age on the variability of pediatric bone age determined using the Greulich and Pyle standards. AJR Am J Roentgenol (2001) 1.63
Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res (1984) 1.58
Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene (1992) 1.57
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer (2007) 1.53
Imaging features of avulsion injuries. Radiographics (1999) 1.53
Association of involvement in psychological self-regulation with longer survival in patients with metastatic cancer: an exploratory study. Adv Mind Body Med (2000) 1.48
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer (2009) 1.47
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res (2001) 1.47
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet (2001) 1.46
Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet (1978) 1.40
Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res (1987) 1.40
Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry (1994) 1.38
Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Cytometry (2001) 1.36
Factors associated with non-urgent utilization of Accident and Emergency services: a case-control study in Hong Kong. Soc Sci Med (2000) 1.35
Human papillomavirus-11 DNA in a patient with chronic laryngotracheobronchial papillomatosis and metastatic squamous-cell carcinoma of the lung. N Engl J Med (1987) 1.32
Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors. Br J Cancer (1977) 1.30
Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol (1995) 1.27
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). Oncol Rep (1998) 1.26
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood (1999) 1.24
Effect of helium on maximal expiratory flow in patients with asthma before and during induced bronchoconstriction. Am Rev Respir Dis (1976) 1.22
Immunohistochemical detection of proliferating cells in vivo. J Histochem Cytochem (1987) 1.22
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res (2000) 1.20
Hepatocarcinomas, cholangiocarcinomas, and hepatoblastomas produced by chemically transformed cultured rat liver epithelial cells. A light- and electron-microscopic analysis. Am J Pathol (1987) 1.19
Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer (2004) 1.17
Simultaneous detection of mitochondrial respiratory chain activity and reactive oxygen in digitonin-permeabilized cells using flow cytometry. Cytometry (2000) 1.14
Emergence of neoplastic transformants spontaneously or after exposure to N-methyl-N'-nitro-N-nitrosoguanidine in populations of rat liver epithelial cells cultured under selective and nonselective conditions. Am J Pathol (1989) 1.13
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol (1999) 1.13
Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol (1999) 1.13
Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res (2001) 1.12
Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene (2011) 1.12
Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients. Cancer Res (1984) 1.11
Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer (1983) 1.11
Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology (1984) 1.11
How to minimize inappropriate utilization of Accident and Emergency Departments: improve the validity of classifying the general practice cases amongst the A&E attendees. Health Policy (2003) 1.10
Giant bronchial carcinoid tumors: a multidisciplinary approach. Ann Thorac Surg (2001) 1.10
Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol (2000) 1.09
The influence of age on the DNA ploidy levels of breast tumours. Eur J Cancer Clin Oncol (1983) 1.09
Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets. Q J Med (1987) 1.08
Contamination of mononuclear cell suspensions obtained from cancer patients by the Böyum method. Br J Cancer (1978) 1.08
Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res (1995) 1.07
Clonal isolation of populations of gamma-glutamyl transpeptidase-positive and -negative cells from rat liver epithelial cells chemically transformed in vitro. Cancer Res (1985) 1.05
Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J Immunol (2001) 1.05
Pathogenesis of pulmonary infarction. Am J Med (1982) 1.05
Management of occluded biliary Wallstents. Gut (1998) 1.04
Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review. Curr Oncol (2012) 1.04
Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture. Cancer Res (1988) 1.04
Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol (1997) 1.03
Expression of transforming growth factor-alpha in primary human colon and lung carcinomas. Br J Cancer (1990) 1.02
Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res (1999) 1.02
Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lung carcinoma cell lines. Am J Pathol (1993) 1.01
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol (2013) 0.99
The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material. Eur J Cancer Clin Oncol (1987) 0.99
The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm. Brain Res (1993) 0.99
Clonal cosegregation of tumorigenicity with overexpression of c-myc and transforming growth factor alpha genes in chemically transformed rat liver epithelial cells. Cancer Res (1991) 0.98
Clonal analysis of tumorigenicity and paratumorigenic phenotypes in rat liver epithelial cells chemically transformed in vitro. Cancer Res (1985) 0.98
Phenotypic and karyotypic changes induced in cultured rat hepatic epithelial cells that express the "oval" cell phenotype by exposure to N-methyl-N'-nitro-N-nitrosoguanidine. Am J Pathol (1985) 0.98
Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol (1988) 0.97
Characterization of human bronchial epithelial cells immortalized by the E6 and E7 genes of human papillomavirus type 16. Exp Cell Res (1994) 0.97
Measurement of intracellular pH. Methods Cell Biol (1990) 0.96
Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res (2002) 0.95
Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. Br J Cancer (1985) 0.95
Factors associated with pulmonary infarction. A discriminant analysis study. Am J Clin Pathol (1985) 0.95
Establishment of propagable epithelial cell lines from normal adult rat pancreas. Exp Cell Res (1987) 0.95
Malignant rhabdoid tumor of the colon. Report of a case with molecular analysis. Dis Colon Rectum (1996) 0.94
Monocytes and macrophages in malignant melanoma. III. Reduction of nitroblue tetrazolium by peripheral blood monocytes. Br J Cancer (1978) 0.94
Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood (2001) 0.94
Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun (2001) 0.94
Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia (2000) 0.93
Flow cytometric measurement of lipid peroxidation in vital cells using parinaric acid. Cytometry (1992) 0.93
ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer (1997) 0.92
Gradation of carcinogen-induced capacity for anchorage-independent growth in cultured rat liver epithelial cells. Cancer Res (1985) 0.92
Dermatomyositis and pregnancy. Obstet Gynecol (1985) 0.91
Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab Invest (1999) 0.91
Binary tree-structured vector quantization approach to clustering and visualizing microarray data. Bioinformatics (2002) 0.90
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma (2000) 0.90
Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun (2001) 0.90
Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis. Postgrad Med J (1975) 0.89
Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res (1997) 0.89
Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene (1999) 0.89
Implications for therapy of drug-metabolizing enzymes in human colon cancer. Cancer Res (1989) 0.89
Phenotypic modulation during tumorigenesis by clones of transformed rat liver epithelial cells. Cancer Res (1987) 0.88
Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys (1999) 0.88